Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Receptor Biologix

Request full access

Receptor-based biological therapeutics for cancer, inflammatory, and autoimmune diseases

Palo Alto, United StatesFounded 2003Biotech & Life Sciences

About Receptor Biologix

Receptor BioLogix, Inc. operated as a biopharmaceutical company focused on developing biological therapeutics for cancer and other complex diseases. Founded in 2003 with an exclusive technology license from Oregon Health Sciences University, the company was established by Michael Shepard, Ph.D., a scientist known for his contributions to the development of Herceptin®. The firm's primary business was centered on drug discovery and development, specifically targeting the human EGF receptor (HER) family of pathways, which are dysregulated in many solid cancers.

The company's core technology revolved around two main platforms. The first was the development of "Hermodulins," also known as pan-HER ligand traps. These were engineered fusion proteins designed to block the various ligands that stimulate tumor growth by inhibiting the compensatory feedback mechanisms that often limit the effectiveness of other cancer drugs. This approach showed significant anti-cancer potential in preclinical studies. The second platform was its Intron Fusion Protein (IFP™) technology, aimed at discovering new, naturally occurring forms of human proteins with therapeutic potential. In July 2006, the company expanded its pipeline by acquiring the assets of Aphton Corp., including the therapeutic cancer vaccine Insegia, which was studied for gastrointestinal cancers.

Throughout its operation, Receptor BioLogix was a privately held entity, funded by venture capital. Its investors included Domain Associates, EW Healthcare Partners, MedImmune Ventures, and New Science Ventures. The company went through several leadership changes, with Thomas A. Glaze appointed CEO in 2006, followed by Dale R. Pfost, Ph.D., in late 2008. This final CEO appointment coincided with an additional $6 million financing round to advance the pan-HER program. The company's journey culminated on January 29, 2009, when its technology and programs were acquired by the Danish biopharmaceutical company Symphogen A/S, which specialized in recombinant polyclonal antibodies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
6
Open positions
None listed
Dealroom signal
22.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Apr 2005 $34M $134M Essex Woodlands Health Ventures · Domain Associates · Northwest Technology Ventures · Skyline Ventures —
SEED✓Equity / VC Jun 2003 $40K $160K Takeda Ventures —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Receptor Biologix website traffic

Latest recorded traffic for Receptor Biologix is 0 monthly website visits. Receptor Biologix's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Receptor Biologix in the Palo Alto ecosystem

Live from Dealroom

The Receptor Biologix office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Takeda Ventures

Series A5 investors entered at this stage

  • Essex Woodlands Health Ventures
  • Domain Associates
  • Northwest Technology Ventures
  • Skyline Ventures
  • MedImmune Ventures

Other known investors1 additional known investor

  • EW Healthcare Partners
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Palo Alto HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Receptor Biologix on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Receptor Biologix’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.